CTLA4 and melanoma: An anti‐CTLA‐4 antibody named ipilimumab was approved by the FDA for treating patients with advanced melanoma in 2011.118 When ipilimumab cooperated with SRS, a median survival was increased from 4.9 to 21.3 months, along with a 2‐year survival rate from 19.7% to 47.2%.119 Intracranial disease control rates are reported as 10% and 24% in patients with stable BM and those with asymptomatic BM respectively.120 Nivolumab and pembrolizumab, both of them against PD‐1, have gained durable clinical response in patients with advanced melanoma and metastatic NSCLC.